La Jolla Pharmaceutical Co. (NASDAQ:LJPC)’s share price fell 3.8% during trading on Thursday . The stock traded as low as $16.62 and last traded at $16.81, with a volume of 61,639 shares changing hands. The stock had previously closed at $17.47.

Several brokerages have commented on LJPC. Jefferies Group reissued a “buy” rating on shares of La Jolla Pharmaceutical in a research report on Wednesday, June 8th. Zacks Investment Research lowered La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday, June 15th. SunTrust Banks Inc. began coverage on La Jolla Pharmaceutical in a research report on Wednesday, June 22nd. They set a “buy” rating and a $30.00 price objective for the company. Finally, Lake Street Capital began coverage on La Jolla Pharmaceutical in a research report on Tuesday, May 24th. They set a “buy” rating and a $25.00 price objective for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. La Jolla Pharmaceutical has an average rating of “Buy” and an average target price of $39.50.

The company’s market capitalization is $310.32 million. The firm’s 50-day moving average is $16.68 and its 200 day moving average is $17.49.

La Jolla Pharmaceutical (NASDAQ:LJPC) last released its earnings results on Friday, May 6th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by $0.22. Analysts anticipate that La Jolla Pharmaceutical Co. will post ($3.99) EPS for the current fiscal year.

An institutional investor recently raised its position in La Jolla Pharmaceutical stock. P.A.W. Capital Corp raised its stake in shares of La Jolla Pharmaceutical Co. (NASDAQ:LJPC) by 5.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 50,400 shares of the biopharmaceutical company’s stock after buying an additional 2,400 shares during the period. La Jolla Pharmaceutical makes up 1.5% of P.A.W. Capital Corp’s holdings, making the stock its 28th largest position. P.A.W. Capital Corp owned about 0.28% of La Jolla Pharmaceutical worth $1,361,000 as of its most recent filing with the SEC.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.